ReviewInternational journal of molecular sciences2018
Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 259 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
259 citing papers in PubMed, 2 syntheses or guidelines pooled it, 510 citations in OpenAlex.
- Vascular Endothelial Growth Factor and the Pathogenesis of Intracranial Aneurysms: A Systematic Review on the Missing Link in a Complex Pathway.Journal of the American Heart Association · 2024Pooled it
- What Went Wrong with VEGF-A in Peripheral Arterial Disease? A Systematic Review and Biological Insights on Future Therapeutics.Journal of vascular research · 2022Pooled it
- [A prospective randomized controlled study of antibiotic bone cement in the treatment of diabetic foot ulcer].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2023Trial
- Deconvoluting the multi-faceted roles of alternative splicing events in cancer: From underlying mechanisms to innovative therapeutics.Acta pharmaceutica Sinica. B · 2026Review
- Angiogenic Doping: Plausible Yet Difficult to Detect.Sports medicine (Auckland, N.Z.) · 2026Review
- New perspectives on VEGF signalling in Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2026Review
- On the structural identifiability of nonlinear models of ligand binding dynamics.Journal of pharmacokinetics and pharmacodynamics · 2026Article
- Targeting stiffness-dependent YAP/TAZ restores angiogenesis dynamics impaired by ALK1 knockout in silico.PLoS computational biology · 2026Article
- Polyphenol-Rich Duhuo Jisheng Decoction Enhances Mesenchymal Stem Cell-Derived Exosome-Mediated Chondroprotection via PI3K/AKT Signaling in Osteoarthritis.Food science & nutrition · 2026Article
- A tri-specific EGFR/cMet/VEGF antibody demonstrates potent multi-mechanistic activity in preclinical triple-negative breast cancer models.The Journal of biological chemistry · 2026Article
- Aqueous Humor Cytokine Profiles in Congenital Cataracts With Posterior Polar Abnormality and Associations With Postoperative Complications.Investigative ophthalmology & visual science · 2026Article
- VEGF and Neurotrophins Interaction in the Retinal Neurovascular Unit Homeostasis: A Target for Ocular Disease Treatment and Management.Pharmaceutical research · 2026Review
- Panaxadiol promotes angiogenesis against chronic cerebral hypoperfusion injury through the VEGF-A/p38 MAPK/Src signaling pathway.Journal of ginseng research · 2026Article
- Ginsenoside Re regulates PFKFB3-mediated glycolysis to inhibit endothelial cell migration to ameliorate atherosclerosis.Journal of ginseng research · 2026Article
- The role of the vascular niche in regulating kidney tubulointerstitial fibrosis.Kidney international · 2026Review
- Molecular Dynamics and Experimental Validation of Natural Products from Chuanxiong Rhizoma as VEGFR2 Inhibitors for nAMD Therapy.ACS omega · 2026Article
- An in silico approach to peptide-based dual-receptor targeting for IL13RA2 and VEGFR-2 extracellular domain.Journal of molecular modeling · 2026Article
- Deciphering the anti-atherosclerotic mechanisms of Danggui-Chuanxiong herb pair: a synergistic approach combining computational prediction andFrontiers in cardiovascular medicine · 2026Article
- Brain neurovascular unit biomarkers: a hypothesis-driven paradigm to advance understanding of post-cardiac arrest cerebral injury.Annals of intensive care · 2026Review
- Pharmacological Treatment for Diabetic Macular Edema: A 2025 Update on Durability and Multi-Target Therapies.Drug design, development and therapy · 2026Review
199 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Vascular endothelial growth factor-A (VEGF-A) is a key mediator of angiogenesis, signalling via the class IV tyrosine kinase receptor family of VEGF Receptors (VEGFRs). Although VEGF-A ligands bind to both VEGFR1 and VEGFR2, they primarily signal via VEGFR2 leading to endothelial cell proliferation, survival, migration and vascular permeability. Distinct VEGF-A isoforms result from alternative splicing of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.